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a r t i c l e s Integrins are α/β heterodimeric cell adhesion receptors that consist of a bilobular head and two legs that span the plasma membrane 1, 2 . Integrins are unusual receptors, as they normally exist on the cell surface in an inactive state (i.e., unable to engage physiologic ligand). This is critical for integrin biology, as it allows, for example, patrolling blood platelets and immune cells to circulate with minimal aggregation or interaction with vessel walls. Physiologic stimuli (for example, chemokines), acting through the short integrin cytoplasmic tails, induce allosteric changes in the ectodomain that are required for extracellular ligand binding ('inside-out' activation) 3 . Binding of physiologic ligands induces 'outside-in' signaling by initiating additional structural rearrangements in the ectodomain 4 , which induce conformational epitopes (ligand-induced binding sites, or LIBS) such as those recognized by the monoclonal antibodies AP5 (ref. 5), LIBS-1 and LIBS-6 (ref. 6 ). These ligand-induced structural rearrangements trigger cell spreading 7 through connections between the integrin cytoplasmic tails and filamentous actin 8 . Disruption of these processes contributes to the pathogenesis of many diseases [9] [10] [11] .
Despite the clinical efficacy of cyclic RGD-like molecules that target platelet integrin α IIb β 3 in preventing thrombosis, parenteral ligand-mimetic antagonists of α IIb β 3 , such as the cyclic heptapeptide eptifibatide, can induce severe thrombocytopenia-a major life-threatening complication-in up to 2% of treated patients 12 . In addition, during oral therapy of acute coronary syndromes, RGD-mimetic drugs paradoxically induced thrombosis and mortality, contributing to the failure of clinical trials 9 .
Crystal structures of integrin ectodomains in complex with small RGD-based peptidomimetics 13, 14 show the RGD motif binding the integrin head: arginine contacts the propeller domain of the α subunit, and aspartic acid binds the βA domain of the β subunit at a metal ion-dependent adhesion site (MIDAS) through Mg 2+ (or Mn 2+ ). Two regulatory Ca 2+ cations at the ligand-associated metal-binding site (LIMBS or synergistic metal-binding site, SyMBS) and adjacent to MIDAS (ADMIDAS) flank the MIDAS metal ion 13 . The Ca 2+ at ADMIDAS links the N-and C-terminal helices of the βA domain, stabilizing the inactive conformation 15 . Binding of ligand-mimetic compounds is mechanically coupled to tertiary changes in the βA domain, involving inward movement of the N-terminal α1 helix toward the MIDAS, forcing reorganization of the loop between the C-terminal F strand and α7 helix, a one-turn displacement of helix α7 and a hybrid domain swing out (reviewed in ref. 3 ). These movements may persist after dissociation of these compounds, contributing to immune thrombocytopenia 16 and facilitating physiologic ligand binding to a 'primed' integrin, an effect that may have contributed to the increased mortality observed in patients treated with RGD-mimetic compounds targeting platelet α IIb β 3 (ref. 17) . RGD-containing α V β 3 antagonists (for example, cilengitide 18 ) can paradoxically stimulate model tumor growth and angiogenesis 19 , possibly through partial agonism of α V β 3 . A recent attempt to address the issue of partial agonism used a non-RGD small molecule that acts competitively to destabilize Mg 2+ at MIDAS in integrin α IIb β 3 , an effect that is reversed at higher Mg 2+ concentrations 20 . So far, however, no RGD-based pure antagonists have been identified.
In the modular matrix protein fibronectin (FN), the 10-kDa wtFN10 is necessary and sufficient for binding to α V β 3 (ref. 21) . Here we report the first crystal structure of an integrin α V β 3 ectodomain bound to a r t i c l e s a physiologically relevant ligand: the FN10 domain. We show that in contrast to wtFN10, a high-affinity form of this ligand (hFN10) acts as a pure antagonist for α V β 3 . To clarify the structural basis for this activity, we also determined the crystal structure of hFN10α V β 3 . Comparisons of the structures revealed a novel mechanism underlying pure antagonism by an RGD-containing ligand that suggests a path to the generation of RGD-based drugs that can act as pure antagonists.
RESULTS

Binding of hFN10 to resting and activated cellular a V b 3
We compared the integrin binding properties of wtFN10 to those of a high-affinity form, hFN10, that was selected for specific α V β 3 binding from a FN10 phage display library, in which five residues N-and C-terminal to the RGD motif were randomized 22 . In hFN10, the sequence 1492 PRGDWNEG 1499 replaces 1492 GRGDSPAS 1499 of wtFN10. Interestingly, RGDWN is also the core sequence in the disintegrin barbourin (on which the drug eptifibatide was based 23 ), excepting an arginine-to-lysine substitution, which enhances the specificity of barbourin for platelet α IIb β 3 over α V β 3 (ref. 14) .
The binding of fluoresceinated fluid-phase wtFN10 to stably expressed wild-type α V β 3 in K562 cells (K562-α V β 3 ) was a low background in physiological concentrations of Ca 2+ and Mg 2+ (Ca 2+ -Mg 2+ , 1 mM each) ( Fig. 1a) , as we expected, because soluble physiologic ligands do not bind to the inactive integrin in physiological Ca 2+ -Mg 2+ -containing buffers. Binding of soluble wtFN10 was increased ten-fold in the presence of the integrin activator Mn 2+ , a mimic of inside-out activation 24 (Fig. 1a) , or was increased six-fold by an N339S mutation in the βA domain, which constitutively activates α V β 3 both in vitro and in vivo 25 (Fig. 1b) . By contrast, strong binding of soluble fluoresceinated hFN10 to K562-α V β 3 occurred in Ca 2+ -Mg 2+ (six-fold compared to that of wtFN10), and was increased a further ~1.5-fold by Mn 2+ (Fig. 1a ). Binding of hFN10 was similar both on wild-type α V β 3 and α V β 3 N339S , each of which was transiently expressed on HEK293T cells (Fig. 1b) .
Effects of hFN10 binding to a V b 3
The integrin activator Mn 2+ induces expression of the epitopes of LIBS monoclonal antibodies (mAbs) AP5 (ref. 5), LIBS-1 and LIBS-2 (ref. 6) , each of which recognizes distinct epitopes in the β 3 subunit. The mAb AP5 recognizes an N-terminal sequence in the PSI (plexinsemaphorin-integrin) domain 5 , the mAb LIBS-1 recognizes a different epitope from AP5 and LIBS-6 binds the C-terminal membrane proximal βTD domain. LIBS expression is further increased after binding of physiologic ligand 5 .
As we expected, Mn 2+ -driven binding of wtFN10 to K562-α V β 3 increased the expression of the LIBS for mAbs AP5, LIBS-1 and LIBS-6 above that induced by Mn 2+ alone ( Fig. 1c) . In contrast, binding of hFN10 not only failed to induce LIBS expression but also substantially decreased LIBS expression induced by Mn 2+ alone ( Fig. 1c) . We saw this effect whether α V β 3 was expressed artificially (on K562 cells) or constitutively (on melanoma M21 cells). And whereas binding of wtFN10 to the constitutively active α V β 3 N339S integrin increased AP5 epitope expression by approximately two-fold, binding of hFN10 did not ( Fig. 1d ). npg a r t i c l e s It is known that Mn 2+ or the binding of soluble RGD-based ligands induces conformational changes in the α V β 3 ectodomain, as detected by changes in the hydrodynamic radius of the ectodomain 4, 26, 27 . We therefore examined the effects of binding of hFN10 to the α V β 3 ectodomain in solution by comparing the hydrodynamic radii of α V β 3 -hFN10 and α V β 3 -wtFN10 complexes by molecular sieve chromatography 4, 27 . We performed chromatography on preformed α V β 3 -hFN10 and α V β 3 -wtFN10 complexes ( Supplementary Fig. 1a ) on a molecular sieve column equilibrated in the relevant metal ion-containing buffer, and we derived Stokes' radii as described previously 4 . The complexes displayed markedly different profiles ( Fig. 1e and Supplementary Fig. 2b ): wtFN10 increased the Stokes' radius (Rs) of α V β 3 in Mn 2+ (6.6 nm) compared to the integrin size in Mn 2+ alone (Rs = 6.3 nm), as we expected. However, hFN10 had little effect on the Rs of α V β 3 in Mn 2+ (6.3 nm) or in Ca 2+ -Mg 2+ (6.0 nm compared to 5.9 nm in the absence of hFN10).
Cell spreading is a reporter of ligandinduced outside-in signaling 28 . To determine the effect of hFN10 on spreading, we compared the spreading of α V β 3 -expressing cells on surfaces coated with native full-length FN (positive control) ( Fig. 1f) , wtFN10 ( Fig. 1f ,g) or hFN10 ( Fig. 1f,h) . After 2 h, approximately 90% of attached cells spread on native FN, and 60% spread on wtFN10. In contrast, less than 20% of attached cells spread on hFN10. Cell attachment under all conditions was eliminated when assays were carried out in the presence of the function-blocking LM609 mAb against α V β 3 (data not shown).
Crystal structures of a V b 3 -wtFN10 and a V b 3 -hFN10 complexes
To clarify the structural basis for the inhibitory effects of bound hFN10 on conformational changes and function of α V β 3 , we soaked ligands hFN10 or wtFN10 into crystals of the α V β 3 ectodomain 4 in 2 mM MnCl 2 and determined the crystal structures of the resulting α V β 3 -hFN10 and α V β 3 -wtFN10 complexes ( Fig. 2a,b, Supplementary Fig. 2 and Table 1 ). hFN10-or wtFN10-bound α V β 3 remained genuflected, with each ligand bound at the integrin head, as we expected. However, orientation of FN10 relative to the βA domain differed markedly between the two complexes, with a ~60° rotation around the RGD loop ( Fig. 2c) . F o − F c omit maps (generated after omitting the FN10 ligand) revealed clear positive densities ( Supplementary Fig. 2c,d) , reflecting stable engagement of the integrin head by ligand. The omit maps showed clear density for the complete hFN10 domain but for only ~60% of wtFN10 (that portion facing the integrin), with the wtFN10 portion farthest away from the integrin showing minimal density, consistent with its low affinity and the likely flexibility of this region in the crystal.
The RGD motif of each ligand bound the α V β 3 head in an identical manner ( Fig. 3a,b) , and as shown previously for the RGDcontaining pentapeptide cilengitide 13 , RGD inserted into the crevice between the propeller and βA domains and contacted both. The α V β 3 -wtFN10 interface was modestly larger than the α V β 3cilengitide interface, mainly because of contacts wtFN10 made with the glycan at the propeller residue Asn266, which included hydrogen bonds with mannose 2271 (MAN2271) ( Fig. 3a ). An N266Q npg a r t i c l e s substitution in cellular α V β 3 did not impair heterodimer formation (as judged by binding of the heterodimer-specific mAb LM609; data not shown) but did reduce the adhesion of HEK293T cells expressing the constitutively active mutant integrin α V N266Q β 3 N339S to immobilized full-length FN by 56% compared to adhesion mediated by α V β 3
N339S
in Ca 2+ -Mg 2+ buffer (P = 0.003, n = 3 independent experiments) ( Supplementary Fig. 3a) .
One structural feature that coincided with the higher affinity of hFN10 compared to wtFN10 was the more extensive α V β 3 -hFN10 interface, which was largely due to the additional and distinct contacts hFN10 made mainly with the MIDAS face and with the specificitydetermining loop of the βA domain (Fig. 3b) . These contacts contributed to the different orientation of hFN10 on α V β 3 and the coordination patterns of the Mn 2+ ion at MIDAS and ADMIDAS (Fig. 3b) . In contrast to the α V β 3 -wtFN10 interface, hFN10 made no contacts with the propeller glycan at Asn266. At the center of the hFN10-βA contacts was a π-π edge-to-face interaction of the mutant Trp1496 in hFN10 with Tyr122 in the α1 helix of βA ( Fig. 3b) . Tyr122 also hydrogen bonded to Glu1462 of hFN10, which formed a salt bridge with Lys125 of βA. The hydroxyl oxygen of hFN10 Tyr1446 also coordinated the Mn 2+ at ADMIDAS through a water molecule. The outcome of these interactions was that the tertiary changes induced by the physiologic ligand wtFN10 (i.e., inward movement of the N-terminal α1 helix toward MIDAS and reorganization of the C-terminal F strand and α7 loop) were absent in the hFN10-bound βA domain (Fig. 3c) . Indeed, the structure of hFN10-bound βA was superimposable on that of the unliganded βA domain (Fig. 3c) . That is to say, the hFN10-bound βA domain assumed the same conformation as the unliganded βA domain. The hFN10-bound α V β 3 structure also displayed other features of an inactive state 4 that were absent from the α V β 3 -wtFN10 structure. These included electrostatic interactions between the two subunits at the β-subunit 'knee' (β-genu) (Supplementary Fig. 3b ) and between βA and βTD within the β 3 subunit ( Supplementary  Fig. 3c ). Together these findings suggest that when bound to hFN10, α V β 3 was at or close to an inactive ground state that would not transduce outside-in signals, despite ligand occupancy.
The Trp1496-Tyr122 π-π interaction was crucial for blocking conformational changes induced by the binding of ligand, as shown in mutational studies. Removing the Trp1496 side chain through Trp1496 substitution to serine (hFN10W/S) converted hFN10 into a partial agonist that could induce binding of the LIBS mAb AP5 to cellular α V β 3 (Fig. 3d) 29 . Similarly, when the Tyr122 side chain was removed through a tyrosine-to-alanine mutation in the βA domain, hFN10-bound α V β 3 Y122A also expressed LIBS (Fig. 3d) .
Reorienting Trp1496 converts hFN10 into a partial agonist
The core RGDWN sequence in hFN10 matches that in barbourin, a partial agonist of α IIb β 3 . Yet superposition of the RGD-containing loops in hFN10, barbourin (PDB 1Q7J) and the drug eptifibatide (PDB 2VDN 14 ) revealed drastically different orientations of the tryptophan side chain in hFN10 compared to those in barbourin and eptifibatide. In contrast to the Trp1496 side chain in hFN10, this tryptophan side chain points inwards toward the center of the RGD loop in the barbourin and eptifibatide structures, away from (Fig. 4a) . Binding of either barbourin or eptifibatide induces expression of AP5 LIBS 14 .
We attempted to modify the orientation of the Trp1496 side chain in hFN10 to resemble that in barbourin or eptifibatide. We mutated three loop residues (underlined) flanking the RGDWN sequence in hFN10 (TPRGDWNE) to match the barbourin sequence (IAKGDWND) and purified this domain (hFN10/B). The crystal structure of the α V β 3 -hFN10/B complex (Supplementary Fig. 4 ) showed that the main chain and side chain structures of the RGD-loop residues IARGDWN were clear in the F o -F c omit map ( Supplementary  Fig. 4) , but the rest of the hFN10/B domain was not visible, likely reflecting flexibility at the new N and C termini of the RGDcontaining loop. It was clear, however, that the main chain structure of this loop changed to position the Cα and Cβ of Trp1496 in the α V β 3 -hFN10/B complex, as in barbourin or eptifibatide (Fig. 4b) , with the Trp1496 side chain in hFN10/B repositioned so that it no longer faces the Tyr122 side chain of βA (Fig. 4c) . This reorientation was associated with the unhindered inward movement of Tyr122 in the α1 helix, as in the eptifibatide-bound integrin 14 . The binding of hFN10/B to cellular α V β 3 consistently induced expression of the LIBS for mAb AP5, similar to that induced by wtFN10 ( Fig. 4d and  Supplementary Fig. 5 ).
DISCUSSION
In this study we report the crystal structures of integrin α V β 3 in complex with an RGD-bearing domain of the physiologically relevant macromolecular ligand fibronectin (wtFN10) and with a high-affinity form of this domain of fibronectin (hFN10) carrying substitutions adjacent to the RGD sequence. Our major finding is that hFN10 unexpectedly acts as a pure antagonist of α V β 3 and lacks the partial agonism of native ligands that is also observed in other RGD-like ligands.
When it bound to cellular α V β 3 , hFN10, unlike wtFN10, did not induce activation-specific conformational LIBS mAb epitopes in the integrin N-and C-terminal domains, and it reduced LIBS expression induced by both the activating cation Mn 2+ and the constitutive (mutational) activation of α V β 3 . In addition, hFN10 bound to but did not substantially alter the hydrodynamic behavior of the soluble α V β 3 ectodomain, unlike wtFN10 or cyclic RGD-based peptides 4 . Cell spreading on immobilized hFN10 was also significantly reduced compared with wtFN10 (P = 0.002) and was substantially reduced compared with native FN. Cell spreading reports outside-in signaling by ligand-occupied integrins 28 .
The α V β 3 -hFN10 structure defines the interface an integrin makes with a macromolecular physiologic ligand. Interestingly, this interface was surprisingly modest even relative to the α V β 3cilengitide interface 13 and was distinguished by contacts with the glycan at Asn266 of the α-subunit propeller domain. These contacts significantly (P = 0.003) contributed to the adhesion function of cellular α V β 3 (Supplementary Fig. 3a) . The glycan at Asn266 is conserved in the fibronectin receptor α 5 β 1 (ref. 30) , and mutation of the equivalent residue in α 5 (N275Q) impaired α 5 β 1 -mediated cell adhesion 31 , suggesting that the glycan contact may also be in the α 5 β 1 -FN interface. This interface is also expected to be more robust than the α V β 3 -FN interface because of an interaction of FN-type III domain 9 with the α-subunit propeller, an interaction that is not used by α V β 3 (ref. 21) . This may explain the greater susceptibility of the smaller α V β 3 -FN interface to force-induced binding or unbinding events, which may make it more suitable than the more extensive α 5 β 1 -FN interface for mediating dynamic outside-in signal transduction 32 . Thus, the wtFN10-α V β 3 structure provides a molecular explanation for the distinct cellular responses seen when different integrins bind to the same ligand domain.
The structure of the α V β 3 -hFN10 complex identified a basis for the unexpected action of hFN10 as a pure antagonist despite its prototypical RGD motif. Structural and mutational studies support a critical role for the novel Trp1496-Tyr122 π-π interaction in 'freezing' the integrin in an inactive conformation. First, removing the Trp1496 side chain from hFN10 resulted in a domain that acted as wtFN10, as reported by LIBS expression. LIBS were also induced by hFN10 binding to cellular α V β 3 lacking the Tyr122 side chain. Second, changing the orientation of the Trp1496 side chain in hFN10 so that it no longer faced Tyr122 (as seen in the structure of the α V β 3 -hFN10/B complex) also led to induction of LIBS when cellular α V β 3 bound hFN10/B. These data strongly argue that blocking the inward movement of the α1 helix towards MIDAS is sufficient to halt the associated tertiary changes in the βA domain that lead to outside-in signaling. Thus, altering the side chain orientation of Trp1496 by design or selection of its local environment can substantially affect the tertiary or quaternary changes induced by binding of RGD-based ligands. This effect could perhaps be replicated. For example, this may be accomplished in a cyclized form of the RGD-containing loop of hFN10, by changing the orientation of the tryptophan side chain in eptifibatide or by replacing d-phenylalanine with d-tryptophan in a modified form of cilengitide. The critical βA Tyr122 is also conserved in α 5 β 1 (ref. 30 ) and β 2 integrins 33 , which, like α V β 3 , are drug targets 34 . Our results thus clearly suggest a path to structure-based drug design of npg a new generation of ligand-mimetic integrin inhibitors that can act as pure antagonists.
METHODS
Methods and any associated references are available in the online version of the paper.
Accession codes. The coordinates and structure factors of αVβ3-hFN10, αVβ3-wtFN10 and αVβ3-hFN10/B have been deposited in the PDB under accession codes 4MMZ, 4MMX and 4MMY, respectively.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper.
ONLINE METHODS
Reagents and antibodies.
Restriction and modification enzymes were obtained from New England BioLabs Inc. (Beverly, MA). Cell culture reagents were purchased from Invitrogen Corp (San Diego, CA) or Fisher Scientific (Hampton, NH). Human plasma fibronectin was obtained from Sigma-Aldrich (St. Louis, MO). The non-inhibitory mouse mAb AP3 (HB-242, American Type Culture Collection, ATCC) detects the β 3 subunit in all conformations. The mouse mAb AP5, kindly provided by T.J. Kunicki (The Scripps Research Institute), detects residues 1-6 in the PSI domain of the β 3 subunit only in high-affinity or ligandbound states. The mouse mAbs LIBS-1 and LIBS-6 to the human β 3 subunit 6 were kindly provided by M. Ginsberg (University of California, San Diego). LIBS-1 binds a neoepitope distinct from that of AP5, and LIBS-6 binds the βTD (residues 602-690) 5 . The Fab fragment of AP5 was prepared by papain digestion followed by anion exchange and size-exclusion chromatography. The functionblocking and heterodimer-specific mAb LM609 (MAB1976) to α V β 3 (ref. 35 ) was from Millipore (Danvers, MA), and allophycocyanin (APC)-labeled goat antimouse Fc-specific antibody (115-135-207) was from Jackson ImmunoResearch (West Grove, PA).
Plasmids, mutagenesis, protein expression and purification. The human α V β 3 ectodomain was expressed in insect cells and purified as described 36 .
The activating N339S mutation in the β 3 subunit was generated as described 37 . Expression plasmids encoding wild-type human N-terminally His-tagged FN10 (S1417-T1509) were generated by PCR from a plasmid containing human FN7-10 kindly provided by H.P. Erickson (Duke University Medical Center, Durham, NC) 38 . The plasmid encoding His-tagged high-affinity FN10 (hFN10) 22 was PCR generated by replacing the cDNA encoding the loop sequence 1492 GRGDSPAS 1499 in wtFN10 with 1492 PRGDWNEG 1499 . RGD-loop substitutions W1496S and TPRGDWNE to IARGDWND (substituted residues underlined) in hFN10 to produce hFN10W/S and hFN10/B, respectively, were generated using PCR-based mutagenesis with the QuikChange kit (Agilent Technologies), cloned into the bacterial expression plasmid pET11a and verified by DNA sequencing. The double mutation N266Q (in the α V propeller) plus N339S (in the βA domain) and the Y122A mutation were generated by PCR in pcDNA3 expression plasmids and confirmed by DNA sequencing. FN10 forms were expressed in bacteria and purified by affinity chromatography on nickel columns followed by gel filtration. Thrombin-cleaved FN10 was further purified by gel filtration. Protein purity was confirmed by SDS-PAGE.
Cell lines, cell culture and transfection. The human erythroleukemia cell line K562 stably expressing recombinant α V β 3 (K562-α V β 3 ) 4 and the human melanoma cell line M21, which constitutively expresses α V β 3 , have been described previously 39 . Cells were maintained in Iscove's modified Dulbecco's medium plus G418 (0.5-1.0 mg/ml) (K562-α V β 3 ) or RPMI 1640 (M21) supplemented with 10% fetal calf serum (FCS), 2 mM l-glutamine, penicillin and streptomycin. HEK293T (ATCC) cells cultured in DMEM supplemented with 10% FCS, 2 mM l-glutamine, 1 mM sodium pyruvate, penicillin and streptomycin were transiently co-transfected with pcDNA3 plasmids encoding full-length
using Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer's protocol.
Fluorescent labeling of FN10 and mAbs. FN10 and the mAbs AP5 (Fab) and AP3 (IgG) were labeled with N-hydroxysuccinimidyl esters of Fluor 488 (Alexa488) and Alexa647 (Invitrogen), respectively, according to the manufacturer's instructions. Excess dye was removed using Centri-Spin size-exclusion microcentrifuge columns (Princeton Separations, Adelphia, NJ). The final FN10, AP5 and AP3 concentrations and dye-to-protein molar ratios (F/P) were determined spectrophotometrically, giving F/P molar ratios of 1.2 (for FN10) and 3 (for AP5 and AP3).
Ligand binding and flow cytometry. In cellular and biochemical assays in which calcium, magnesium or manganese ions were used, they were each used at final concentrations of 1 mM. Cells stably (K562) or transiently (HEK293T) expressing wild-type or mutant forms of α V β 3 were harvested by incubating in 10 mM EDTA in PBS (5 min, 25 °C), followed by washing three times in HEPES-buffered saline (20 mM HEPES and 150 mM NaCl, pH 7.4) containing BSA (0.1% w/v; washing buffer, WB). 1 × 10 6 cells were suspended in 100 µl WB containing CaCl 2 plus MgCl 2 or MnCl 2 (10 min, 37 °C), and incubated first with Alexa488-labeled wtFN10 or hFN10 (each at 3-10 µg/ml) (30 min, 25 °C) in the dark and then with Alexa647-conjugated AP3 (10 µg/ml) for an additional 30 min on ice. Cells were washed in the respective metal ion-containing buffer, resuspended, fixed in 4% paraformaldehyde and analyzed using FACSCalibur or BD-LSRII flow cytometers (BD Biosciences). Binding of soluble FN10 to α V β 3 + cells was expressed as the mean fluorescence intensity (MFI) determined using FlowJo software. Binding of soluble FN10 to HEK293T cells was normalized by dividing its MFI by the MFI of Alexa647-conjugated AP3 to the same cells and multiplying by 100. The mean and s.d. from independent experiments were calculated and compared using Student's t-test.
LIBS epitope expression. K562-α V β 3 cells, transiently transfected HEK293T cells or α V β 3 + M21 cells (0.5 × 10 6 in 100 µl WB) were incubated in the absence or presence of unlabeled soluble FN10 (5 µg) in Ca 2+ -Mg 2+ or in Mn 2+ (30 min, at 25 °C). Alexa647-labeled AP5 Fab (10 µg/ml), unlabeled anti-LIBS-1 (each to 10 µg/ml) or LIBS-6 ascites (to 1:50 dilution) were added, and the cells were incubated for an additional 30 min before washing. Alexa647-labeled AP3 (10 µg/ml) was used with HEK293T cells in a separate set of tubes for normalization. APC-labeled goat anti-mouse Fc-specific antibody (10 µg/ml) was added to anti-LIBS-1-or anti-LIBS-6-labeled M21 cells for an additional 30 min at 4 °C. Cells were then washed, resuspended, fixed in 4% paraformaldehyde and analyzed by flow cytometry. LIBS epitope expression was measured and expressed as MFI (in the case of K562-α V β 3 or M21 cells) and normalized (in the case of HEK293T cells) as described above.
Hydrodynamic shift assays. The α V β 3 ectodomain was incubated alone or with FN10 (at a 2:1 FN10:integrin molar ratio) in 145 mM NaCl and 25 mM Tris-HCl, pH 7.4 (TBS), containing Ca 2+ , Ca 2+ -Mg 2+ or Mn 2+ (20 °C, 1.5 h). Aliquots were then taken and chromatographed at room temperature on a precalibrated Superdex S-200 GL column equilibrated in buffer having the same metal-ion composition used during the incubation, and Stokes radii were derived as described previously 4 . The elution profiles resolved by molecular sieve chromatography were monitored in-line by UV adsorption at 280 nm. Unliganded with or without FN10-treated α V β 3 species were resolved as single discrete symmetrical peaks. Excess FN10 served as an internal standard. The identity of the resolved peaks was confirmed formally by SDS-PAGE.
Cell adhesion assays. wtFN10, hFN10 or full-length FN (each at a 100 µg/ml in PBS) was adsorbed to demarcated areas in Maxisorp Nunc Omni Tray plates (Sigma-Aldrich, St. Louis, MO) overnight at 25 °C. The various FN-coated surfaces were washed with PBS and blocked with BSA (5% w/v in PBS, 1 h, 25 °C). K562-α V β 3 cells (5 × 10 4 ) were added (in TBS, 1 mM Mn 2+ ) in the absence or presence of the mAb LM609 (10 µg/ml, added 15 min before plating). Cells were incubated (2 h, 37 °C), washed three times in warm TBS and fixed with 4% formaldehyde (in PBS, 25 °C, 10 min). Images were captured using an inverted phase contrast microscope (Zeiss Axiovert 40CFL) fitted with a powershot G12 Cannon Camera. ImageJ 1.48a software (National Institutes of Health, USA) was used to quantify cell spreading of 300-400 randomly selected cells. Spread cells were clearly distinguishable from round, refringent non-spread cells. Representative phase contrast images were collected using a Zeiss Axiovert 35 inverted microscope using a charge-coupled device (CCD) camera and Spot software (Diagnostics Instruments). Adhesion of transiently transfected HEK293T cells expressing equivalent amounts of α V β 3 N339S or α V N266Q β 3 N339S was done by adding cells (3 × 10 4 ) in TBS containing Ca 2+ -Mg 2+ and 0.1% BSA (w/v) to FN-coated surfaces (45 min, 25 °C). Non-adherent cells were removed by washing, and adherent cells were fixed (2% paraformaldehyde, 30 min, 25 °C), stained (0.1% crystal violet, 30 min, 25 °C), washed with water, air dried and then solubilized (1% SDS). Relative cell attachment was estimated by absorbance of the lysates at 540 nm measured using a SpectraMax M2E Microplate reader (Molecular Devices, Sunnyvale, CA).
Crystallography, structure determination and refinement. The α V β 3 ectodomain was crystallized at 4 °C by vapor diffusion using the hanging drop method as previously described 4 . hFN10, wtFN10 or hFN10/B (at 1.5 mM) was soaked into α V β 3 crystals in the crystallization well solution containing 2 mM Mn 2+ for 2-3 weeks. Crystals were harvested in 12% PEG 3500 (polyethylene glycol, molecular weight 3500) in 100 mM sodium acetate, pH 4.5, 800 mM NaCl plus 2 mM Mn 2+ and FN10 (at 1.5 mM), cryoprotected by the addition of glycerol in 2% increments up to a 24% final concentration and then flash frozen in liquid nitrogen. Diffraction data from cryocooled crystals were collected on the ID19 beamline fitted with a CCD detector at the APS Facility (Chicago, IL). Data were indexed, integrated and scaled with the HKL2000 program 40 for α V β 3 -hFN10 and α V β 3 -hFN10/B and with iMosflm 41 for α V β 3 -wtFN10 using the same R free set imported from the PDB ID 3IJE structure factors. Phases were determined by molecular replacement using PHASER 42 , with the structures of the unliganded α V β 3 ectodomain (PDB ID 3IJE) and the FN10 domain (PDB ID 1FNF) used as search models. The resulting models were refined with the 1.8.4 version of Phenix 11 (ref. 43) using simulated annealing, TLS, positional and individual temperature-factor refinement and default restrains. Several cycles of refinement and model building using Coot 44 were applied to refine the complex structures of α V β 3 -hFN10, α V β 3 -wtFN10 and α V β 3 -hFN10/B ( Table 1) , with automatic optimization of X-ray and stereochemistry and additional Ramachandran restrains in the last cycles. The Ramachandran statistics were as follows: α V β 3 -hFN10 structure, 89% in the most favored regions, 10.47% in additional allowed regions and 0.53% outliers; α V β 3 -wtFN10 structure, 89% in the most favored regions, 10.18% in additional allowed regions and 0.82% outliers; α V β 3 -hFN10/B structure, 91% in the most favored regions, 0.56% in additional allowed regions and 0.56% outliers. σA-weighted F o -F c omit maps were generated by removing the FN10 ligand from the final complex models using phenix.maps. All structural illustrations were prepared with the Chimera software 45 .
